It has been demonstrated that irisin acts as a protective factor and a potential biomarker for obesity-related comorbidities, while alterations in myonectin and myostatin further contribute to cardiometabolic risk in MASLD patients [91,92]. The gene discussed is MSTN; the disease is obesity disorder.